www.heavensgatel2.fora.pl

[nlwxpearo]

A new class of anti-hypertension drugs-A Ⅱ receptor antagonist


. In the first 4 weeks, the product exists between 2O ~ 80mg a relatively flat dose-response curve, when the dose was over 80rag no further decline in DBP. Compared with placebo,[link widoczny dla zalogowanych], this product can significantly reduce the supine position than the systolic blood pressure (SBP). This product is visible between each dose group, SBP significantly effect the amount of a relationship. In this study,[link widoczny dla zalogowanych], the product generally easy to tolerate; the most common adverse reactions are dizziness and headache of the product group and the placebo group the rate of adverse reactions were 3O. 39 and 3O. 4. This product is compared with other AI receptor antagonist, has more advantages, including a longer half-Yuan period. And because it is mainly excreted through the bile,[link widoczny dla zalogowanych], it will not involve the kidney side effects. 3A Ⅱ receptor antagonist reported to the domestic development of profiles,[link widoczny dla zalogowanych], Hangzhou MSD Pharmaceutical Co., Ltd. in January 1998 approved losartan potassium tablets repackage the brand name Cozaar; China Pharmaceutical University, is developing losartan and Virginia Chastain; Shanghai Institute of Pharmaceutical Industry is also in the development of Virginia losartan. According to June 17, 1999, Kant losartan and irbesartan have been included in the Novartis Virgin losartan (brand name Diovan) was allowed to enter the first half of 1999 market outlook of China's market by 4 drug market value of 24.7 billion U.S. dollars is from the next century will have to decline, despite the increase in the number of patients with hypertension, the market capacity has been rising. This is because the number of calcium channel blockers too much (CCB), and ACEI will soon lose patent protection, these drugs currently account for more than 75 markets. But the study also said the next century, anti-hypertension drug market will be AI receptor antagonist, this horse a sales from 339 million in 1996 rose to 1.68 billion U.S. dollars in 2005, but the company in 2010 with Novartis Valsartan and SmithMineBeecham Eprosartan the listing of the company to 8.8 billion U.S. dollars, after sales forecast to between the two points 0 2010 the sum of $ 800,000,000 to $ 600,000,000. Datamonitor hypertension drugs to reduce the total market. Another strategy team, according to IMS flexible forecasting system in 2005, the United States with congestive heart failure (CHF) treatment of the total market forecast to reach 1.7 billion treatment days to 8 in 1996 prices. 2.5 billion. decomposition of the severity of the disease the treatment of 53 days showed a CHF drug market, Merck's Losartan in 1998 the market for this new indication for the first AI receptor antagonist. In this scenario,[link widoczny dla zalogowanych], the * 352 *, the Association of '% Norway (China Pressing intelligence} 1999 No. 5 No. 6 IMS forecasts that by 2005, AI receptor antagonist, total income will be 27 and treatment of CHF market for 13 days. ACEI this market accounted for by the first generation of rust, which is expected in 2005 value dropped from 39 to 74 in 1995; treatment at from 31 to 27 in 1995. one of Merck's enalapril treatment in Iraq will peak at 167 million down to 80 million yuan in 2005 , while the Losartan treatment at the same time in up to 58 million yuan. The more a reference text such as Cambodia Mei Ying. Medicine by the information, 1999,10 {10 a l32Mkt.L.199F, Z4 (32) a 173MktL.199F , 24 (32), 154 Xiao. Medicine by the newspaper ,1999 - 5 - 28;} one. f drug label to drugs in the application for registration, must apply for the indication. However, in clinical practice in, you will find some of their other purposes, doctors in clinical practice, with the clinical experience of a nervous system drugs Fen Bian beefy R7 accumulation of drugs will not register for the disease. This paper describes the experience in this area.